MENU
+Compare
EQ
Stock ticker: NASDAQ
AS OF
Jul 8, 04:28 PM (EDT)
Price
$0.32
Change
-$0.00 (-0.00%)
Capitalization
11.14M

EQ Equillium Forecast, Technical & Fundamental Analysis

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need... Show more

Industry: #Biotechnology
EQ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for EQ with price predictions
Jul 08, 2025

EQ's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for EQ moved out of oversold territory on June 24, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where EQ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 08, 2025. You may want to consider a long position or call options on EQ as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EQ just turned positive on June 25, 2025. Looking at past instances where EQ's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EQ advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .

EQ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EQ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.054) is normal, around the industry mean (16.762). P/E Ratio (0.000) is within average values for comparable stocks, (58.794). EQ's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.377). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.364) is also within normal values, averaging (266.862).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EQ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EQ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
EQ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

EQ is expected to report earnings to fall 54.88% to -18 cents per share on August 06

Equillium EQ Stock Earnings Reports
Q2'25
Est.
$-0.19
Q1'25
Missed
by $0.12
Q4'24
Beat
by $0.15
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.16
The last earnings report on May 08 showed earnings per share of -40 cents, missing the estimate of -28 cents. With 117.87K shares outstanding, the current market capitalization sits at 11.14M.
A.I. Advisor
published General Information

General Information

a developer of products for severe immune-inflammatory disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2223 Avenida De La Playa
Phone
+1 858 240-1200
Employees
44
Web
https://www.equilliumbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CXAI1.000.05
+5.22%
CXApp
ACXP0.490.02
+3.63%
Acurx Pharmaceuticals
XRX5.450.18
+3.42%
Xerox Holdings Corp
SXT108.381.15
+1.07%
Sensient Technology Corp
BAH107.57-2.86
-2.59%
Booz Allen Hamilton Holding Corp

EQ and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EQ has been loosely correlated with MTNB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EQ jumps, then MTNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EQ
1D Price
Change %
EQ100%
-2.19%
MTNB - EQ
40%
Loosely correlated
+3.30%
IMNM - EQ
33%
Poorly correlated
-1.61%
PRQR - EQ
28%
Poorly correlated
+2.80%
MURA - EQ
24%
Poorly correlated
+1.61%
WVE - EQ
24%
Poorly correlated
-1.56%
More